ES2200617B1 - Derivados de urea como antagonistas de integrinas alfa 4. - Google Patents

Derivados de urea como antagonistas de integrinas alfa 4.

Info

Publication number
ES2200617B1
ES2200617B1 ES200100126A ES200100126A ES2200617B1 ES 2200617 B1 ES2200617 B1 ES 2200617B1 ES 200100126 A ES200100126 A ES 200100126A ES 200100126 A ES200100126 A ES 200100126A ES 2200617 B1 ES2200617 B1 ES 2200617B1
Authority
ES
Spain
Prior art keywords
antagonists
ord
urea derivatives
urea
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100126A
Other languages
English (en)
Other versions
ES2200617A1 (es
Inventor
Juan Miguel Jimenez Mayorga
Jordi Basch Taña
Jesus Maria Ontoria Ontoria
Eloisa Navarro Romero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200100126A priority Critical patent/ES2200617B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to IL15693902A priority patent/IL156939A0/xx
Priority to AT02710010T priority patent/ATE374191T1/de
Priority to CA002434939A priority patent/CA2434939A1/en
Priority to PL02369120A priority patent/PL369120A1/xx
Priority to US10/466,665 priority patent/US7253171B2/en
Priority to PE20020000372002000023A priority patent/PE20020822A1/es
Priority to HU0303722A priority patent/HUP0303722A3/hu
Priority to UA2003076827A priority patent/UA81603C2/ru
Priority to KR1020037009578A priority patent/KR100861471B1/ko
Priority to SK923-2003A priority patent/SK9232003A3/sk
Priority to PCT/EP2002/000331 priority patent/WO2002057242A2/en
Priority to RU2003125367/04A priority patent/RU2296120C2/ru
Priority to SI200230614T priority patent/SI1383750T1/sl
Priority to CZ20031964A priority patent/CZ20031964A3/cs
Priority to EEP200300327A priority patent/EE200300327A/xx
Priority to HK04101137.8A priority patent/HK1058361B/en
Priority to JP2002557923A priority patent/JP4173003B2/ja
Priority to DE60222647T priority patent/DE60222647T2/de
Priority to ES02710010T priority patent/ES2291448T3/es
Priority to NZ527031A priority patent/NZ527031A/en
Priority to AU2002228048A priority patent/AU2002228048B2/en
Priority to MXPA03006363A priority patent/MXPA03006363A/es
Priority to CNB028065255A priority patent/CN100536839C/zh
Priority to EP02710010A priority patent/EP1383750B1/en
Priority to DK02710010T priority patent/DK1383750T3/da
Priority to BR0206588-6A priority patent/BR0206588A/pt
Priority to PT02710010T priority patent/PT1383750E/pt
Priority to MYPI20020184A priority patent/MY129423A/en
Priority to UY27127A priority patent/UY27127A1/es
Priority to ARP020100181A priority patent/AR032256A1/es
Priority to ZA200305535A priority patent/ZA200305535B/en
Priority to NO20033269A priority patent/NO327002B1/no
Priority to EC2003004707A priority patent/ECSP034707A/es
Priority to BG108004A priority patent/BG108004A/bg
Publication of ES2200617A1 publication Critical patent/ES2200617A1/es
Application granted granted Critical
Publication of ES2200617B1 publication Critical patent/ES2200617B1/es
Priority to US11/802,165 priority patent/US20070238763A1/en
Priority to CY20071101582T priority patent/CY1107086T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)

Abstract

Derivados de urea como antagonistas de integrinas \alpha4, teniendo dichos derivados de urea la Fórmula I:
28
o una sal farmacéuticamente aceptable del mismo, en donde: Y es un arilo monocíclico, o un heteroarilo monocíclico que contiene uno o dos heteroátomos seleccionados entre N, O y S; L1 y L2 son unos átomos o grupos de unión; W es O, S, NH, N(Rc), o NCN; X es -(CH2)_{n}arilo-, o
-(CH2)_{n}heteroarilo-; y Z es un grupo seleccionado entre -C(O)ORd, -P(O)_{2}ORd, -S(O)_{2}ORd, -S(O)_{2}N (Rd) (Rd), -C(O)NH_{2}, -C(O)N(Re)S(O)_{2}Rd, -S(O)_{2}N(Re)C(O)Rd, -5-tetrazolilo, o -C(O)Rd; en la fabricación de un medicamento para uso como un antagonista \alpha4\beta1 y/o \alpha4\beta7. Estos antagonistas son útiles en la inhibición de procesos de adhesión celular que incluyen activación, migración, proliferación y diferenciación celular. La presente invención
describe una serie de derivados de urea, que son útiles en la inhibición y prevención de la adhesión leucocitaria y patologías mediadas por la adhesión leucocitaria. Esta invención también describe composiciones que contienen dichos compuestos, procedimientos para su preparación, y métodos de tratamiento utilizando tales compuestos.
ES200100126A 2001-01-17 2001-01-19 Derivados de urea como antagonistas de integrinas alfa 4. Expired - Fee Related ES2200617B1 (es)

Priority Applications (37)

Application Number Priority Date Filing Date Title
ES200100126A ES2200617B1 (es) 2001-01-19 2001-01-19 Derivados de urea como antagonistas de integrinas alfa 4.
AU2002228048A AU2002228048B2 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
CA002434939A CA2434939A1 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
PL02369120A PL369120A1 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
US10/466,665 US7253171B2 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin α4 antagonists
PE20020000372002000023A PE20020822A1 (es) 2001-01-17 2002-01-15 Derivados de la urea como antagonistas de integrinantagonistas de receptores de histamina as o4
HU0303722A HUP0303722A3 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antanists, process for their preparation and pharmaceutical compositions containing them
UA2003076827A UA81603C2 (ru) 2001-01-19 2002-01-15 ПРОИЗВОДНЫЕ МОЧЕВИНЫ КАК АНТАГОНИСТЫ б4 ИНТЕГРИНА
KR1020037009578A KR100861471B1 (ko) 2001-01-19 2002-01-15 인테그린 알파 4 길항제로서의 유레아 유도체
SK923-2003A SK9232003A3 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
PCT/EP2002/000331 WO2002057242A2 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
RU2003125367/04A RU2296120C2 (ru) 2001-01-19 2002-01-15 Производные мочевины, способы их получения и фармацевтическая композиция на их основе
SI200230614T SI1383750T1 (sl) 2001-01-19 2002-01-15 Derivati uree kot integrin alfa 4 antagonisti
CZ20031964A CZ20031964A3 (cs) 2001-01-19 2002-01-15 Deriváty močoviny jako antagonisté alfa4 integrinů
EEP200300327A EE200300327A (et) 2001-01-19 2002-01-15 Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
HK04101137.8A HK1058361B (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
JP2002557923A JP4173003B2 (ja) 2001-01-19 2002-01-15 インテグリンα４アンタゴニストとしての尿素誘導体
DE60222647T DE60222647T2 (de) 2001-01-19 2002-01-15 Urea derivate als integrin alpha 4 antagonisten
IL15693902A IL156939A0 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
NZ527031A NZ527031A (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
CNB028065255A CN100536839C (zh) 2001-01-19 2002-01-15 作为整联蛋白α4的拮抗剂的脲衍生物
AT02710010T ATE374191T1 (de) 2001-01-19 2002-01-15 Urea derivate als integrin alpha 4 antagonisten
MXPA03006363A MXPA03006363A (es) 2001-01-19 2002-01-15 Derivados de urea como antagonistas de integrinas alfa-4.
EP02710010A EP1383750B1 (en) 2001-01-19 2002-01-15 Urea derivatives as integrin alpha 4 antagonists
DK02710010T DK1383750T3 (da) 2001-01-19 2002-01-15 Urinstofderivater som integrin a4 antagonister
BR0206588-6A BR0206588A (pt) 2001-01-19 2002-01-15 Composto, processo para produzir o mesmo, uso do mesmo, composição farmacêutica, e, método para tratar um paciente afligido com uma condição patológica suscetìvel à melhora pelo antagonismo de integrinas alfa4beta1 e/ou alfa4beta7
PT02710010T PT1383750E (pt) 2001-01-19 2002-01-15 Derivados de ureia como antagonistas da integrina alfa 4
ES02710010T ES2291448T3 (es) 2001-01-19 2002-01-15 Derivados de urea como antagonistas de integrina alfa-4.
MYPI20020184A MY129423A (en) 2001-01-19 2002-01-18 Urea derivatives as integrin 4 antagonists
UY27127A UY27127A1 (es) 2001-01-19 2002-01-18 Derivados de la urea como antagonistas de integrin alfa-4
ARP020100181A AR032256A1 (es) 2001-01-19 2002-01-18 Derivados de la urea como antagonistas de integrin alfa 4".
ZA200305535A ZA200305535B (en) 2001-01-19 2003-07-17 Urea derivatives as integrin alpha 4 antagonists.
EC2003004707A ECSP034707A (es) 2001-01-19 2003-07-18 Derivados de urea como antagonistas de alfa integrado
NO20033269A NO327002B1 (no) 2001-01-19 2003-07-18 Urea-derivater som integrin-alfa-4-antagonister
BG108004A BG108004A (bg) 2001-01-19 2003-07-18 Карбамидни производни като интегрин алфа 4 антагонисти
US11/802,165 US20070238763A1 (en) 2001-01-19 2007-05-21 Urea derivatives as integrin a4 antagonists
CY20071101582T CY1107086T1 (el) 2001-01-19 2007-12-13 Παραγωγα ουριας ως ανταγωνιστες ιντεγκρινης αλφα 4

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100126A ES2200617B1 (es) 2001-01-19 2001-01-19 Derivados de urea como antagonistas de integrinas alfa 4.

Publications (2)

Publication Number Publication Date
ES2200617A1 ES2200617A1 (es) 2004-03-01
ES2200617B1 true ES2200617B1 (es) 2005-05-01

Family

ID=8496447

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200100126A Expired - Fee Related ES2200617B1 (es) 2001-01-17 2001-01-19 Derivados de urea como antagonistas de integrinas alfa 4.
ES02710010T Expired - Lifetime ES2291448T3 (es) 2001-01-19 2002-01-15 Derivados de urea como antagonistas de integrina alfa-4.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02710010T Expired - Lifetime ES2291448T3 (es) 2001-01-19 2002-01-15 Derivados de urea como antagonistas de integrina alfa-4.

Country Status (32)

Country Link
US (2) US7253171B2 (es)
EP (1) EP1383750B1 (es)
JP (1) JP4173003B2 (es)
KR (1) KR100861471B1 (es)
CN (1) CN100536839C (es)
AR (1) AR032256A1 (es)
AT (1) ATE374191T1 (es)
AU (1) AU2002228048B2 (es)
BG (1) BG108004A (es)
BR (1) BR0206588A (es)
CA (1) CA2434939A1 (es)
CY (1) CY1107086T1 (es)
CZ (1) CZ20031964A3 (es)
DE (1) DE60222647T2 (es)
DK (1) DK1383750T3 (es)
EC (1) ECSP034707A (es)
EE (1) EE200300327A (es)
ES (2) ES2200617B1 (es)
HU (1) HUP0303722A3 (es)
IL (1) IL156939A0 (es)
MX (1) MXPA03006363A (es)
MY (1) MY129423A (es)
NO (1) NO327002B1 (es)
NZ (1) NZ527031A (es)
PL (1) PL369120A1 (es)
PT (1) PT1383750E (es)
RU (1) RU2296120C2 (es)
SK (1) SK9232003A3 (es)
UA (1) UA81603C2 (es)
UY (1) UY27127A1 (es)
WO (1) WO2002057242A2 (es)
ZA (1) ZA200305535B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
ES2219177B1 (es) * 2003-05-05 2006-02-16 Almirall Prodesfarma, S.A. Derivados de n-(2-feniletil) sulfamida como antagonistas de la integrina alfa4.
WO2005019193A2 (en) * 2003-08-20 2005-03-03 Smithkline Beecham Corporation Phenylurea derivatives useful in the treatment of conditions mediated by polo-like kinases (plk)
US8008425B2 (en) 2005-08-18 2011-08-30 Nissan Chemical Industries, Ltd. Thiophene compound having sulfonyl group and process for producing the same
JP2009516730A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−アラニン誘導体
KR100588821B1 (ko) * 2006-01-06 2006-06-12 모악개발 주식회사 균일 팽창이 가능한 패커를 구비하는 하수관로 부분보수장치
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 三環式ピラゾロピリジンキナーゼ阻害剤
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2318407B1 (en) 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CA2732765A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
KR101038486B1 (ko) * 2008-09-03 2011-06-01 쌍용건설 주식회사 패커를 이용한 비굴착식 하수관로 보수 장치 및 방법
EP2759535A1 (en) * 2008-12-05 2014-07-30 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
FI20095678A0 (fi) * 2009-06-16 2009-06-16 Biotie Therapies Oy Ureasubstituoituja sulfoniamidijohdannaisia
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
CN102869663A (zh) 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 吡唑并吡嗪激酶抑制剂
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
WO2012031196A1 (en) * 2010-09-03 2012-03-08 Forma Therapeutics, Inc. 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
DK3054936T5 (da) 2013-10-10 2024-03-18 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
JP2023552490A (ja) * 2020-10-16 2023-12-15 セントルイス ユニバーシティ Ｒｅｖ－ｅｒｂアゴニスト

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740611A (en) * 1986-10-30 1988-04-26 The Standard Oil Company N,N'-disubstituted ureas
US4705864A (en) * 1986-11-10 1987-11-10 The Standard Oil Company Aryl oxime derivatives of hydantoins
WO1992008464A1 (en) * 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
AU2603697A (en) * 1996-04-23 1997-11-12 Pharmacia & Upjohn Company Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors
SG124234A1 (en) 1996-07-25 2006-08-30 Biogen Idec Inc Cell adhesion inhibitors
BR9711342A (pt) * 1996-08-22 1999-08-17 Warner Lambert Co Antagonistas de receptor de bombesina nÆo-pept¡do
CA2291708A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
ATE249421T1 (de) 1997-06-23 2003-09-15 Tanabe Seiyaku Co Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
AU749132B2 (en) 1997-08-28 2002-06-20 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
WO1999020617A1 (en) * 1997-10-21 1999-04-29 Active Biotech Ab Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
IL135176A0 (en) 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
EP1034164B1 (en) 1997-11-24 2004-05-19 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
HUP0100178A3 (en) 1997-12-17 2002-12-28 Merck & Co Inc Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
US6221913B1 (en) 1998-01-21 2001-04-24 Zymogenetics, Inc. Dialkyl ureas as calcitonin mimetics
PL348260A1 (en) * 1998-12-16 2002-05-20 Bayer Ag New biphenyl and biphenyl-analogous compounds as integrin antagonists
EP1150997A1 (en) 1999-01-25 2001-11-07 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
JP2002538135A (ja) 1999-03-01 2002-11-12 エラン ファーマシューティカルズ，インコーポレイテッド α４β７レセプターアンタゴニストとして有用なα−アミノ酢酸誘導体
DE19909979A1 (de) * 1999-03-06 2000-09-07 Bayer Ag Verfahren zur Herstellung von Glycokonjugaten von 20(S)-Camptothecin
NZ515248A (en) 1999-05-07 2004-01-30 Texas Biotechnology Corp Heterocyclic substituted carboxylic acid derivatives useful for inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
WO2001014328A2 (en) * 1999-08-20 2001-03-01 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors

Also Published As

Publication number Publication date
UY27127A1 (es) 2002-03-22
HK1058361A1 (en) 2004-05-14
KR100861471B1 (ko) 2008-10-02
US7253171B2 (en) 2007-08-07
ES2291448T3 (es) 2008-03-01
CN1531425A (zh) 2004-09-22
JP4173003B2 (ja) 2008-10-29
JP2004517143A (ja) 2004-06-10
SK9232003A3 (en) 2004-05-04
NO20033269D0 (no) 2003-07-18
EE200300327A (et) 2003-10-15
NO20033269L (no) 2003-09-19
PT1383750E (pt) 2007-12-26
EP1383750A2 (en) 2004-01-28
MY129423A (en) 2007-03-30
ECSP034707A (es) 2003-10-28
DE60222647D1 (de) 2007-11-08
CN100536839C (zh) 2009-09-09
ZA200305535B (en) 2004-10-18
NZ527031A (en) 2005-09-30
BG108004A (bg) 2004-09-30
CY1107086T1 (el) 2012-10-24
NO327002B1 (no) 2009-03-30
PL369120A1 (en) 2005-04-18
WO2002057242A3 (en) 2003-11-27
DE60222647T2 (de) 2008-06-26
RU2003125367A (ru) 2005-01-10
UA81603C2 (ru) 2008-01-25
US20070238763A1 (en) 2007-10-11
DK1383750T3 (da) 2008-01-28
HUP0303722A2 (hu) 2004-03-01
KR20030069219A (ko) 2003-08-25
US20040142982A1 (en) 2004-07-22
CZ20031964A3 (cs) 2004-01-14
BR0206588A (pt) 2004-06-22
EP1383750B1 (en) 2007-09-26
HUP0303722A3 (en) 2005-12-28
IL156939A0 (en) 2004-02-08
RU2296120C2 (ru) 2007-03-27
MXPA03006363A (es) 2004-04-20
ATE374191T1 (de) 2007-10-15
WO2002057242A2 (en) 2002-07-25
ES2200617A1 (es) 2004-03-01
AR032256A1 (es) 2003-10-29
CA2434939A1 (en) 2002-07-25
AU2002228048B2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
ES2200617B1 (es) Derivados de urea como antagonistas de integrinas alfa 4.
EP1590334B1 (en) 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
AR038914A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion para fabricar un medicamento
PE20240143A1 (es) Nuevos derivados de quinazolina como inhibidores de sos1 y uso de los mismos
BR0116379A (pt) Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila
IL156304A (en) RCXC3 antagonists
PE20091371A1 (es) Inhibidores de hsp90
ES2527001T3 (es) Isoquinolinonas y quinazolinonas sustituidas
AR074343A1 (es) Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
BRPI0519288A2 (pt) compostos heterocÍclicos como antagonistas de ccr2b
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
AR041563A1 (es) Derivados de quinazolinona con actividad antagonista del receptor vanilloide humano tipo 1 (vr1) utiles como agentes antihiperalgesicos
KR20020047185A (ko) 퀴나졸리논
PE20061378A1 (es) INHIBIDORES DE LA ACTIVIDAD DE Akt
CN103122002A (zh) 具有抗肿瘤活性的萘醌类化合物
CN103122003A (zh) 具有抗肿瘤活性的萘醌类化合物
TH67254A (th) สารยับยั้งไทโรซีนไคเนสชนิดใหม่
AR120905A1 (es) Derivados de [1,2,4]triazolo[4,3-a]quinazolina como moduladores de la diacilglicerol-quinasa
TH159356A (th) สารประกอบและวิธีการสำหรับการยับยั้งความก้าวหน้าเชิงไมไทติก
TH69667A (th) ฟิวสด์เฮเทอโรไซเคิลชนิดใหม่และการใช้สารเหล่านั้น
TH69088A (th) Cgrp รีเซพเตอร์ แอนทาโกนิสท์
WO2018175670A1 (en) Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same
TH79822A (th) เกลืออะมิเนียมของ 1,2,3-ไทรอะโซล เป็นสารตั้งต้นของยาที่รวมถึงสารต้านไวรัส
TH75083A (th) เฮเทอโรไซเคิลที่ถูกแทนที่และการใช้สารเหล่านั้น
TH68035A (th) อนุพันธ์ควิแนโซลีน

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20040301

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2200617B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20101018